Dr. Michael Koslowski has over 20 years of experience in immunotherapeutic drug discovery and development from positions in academia, biotech and pharmaceutical industry.

Michael joined GammaDelta Therapeutics in 2018 from Mission Therapeutics, where he was Executive Vice President of Research & Development and Chief Medical Officer, responsible for developing Mission’s pipeline of deubiquitinating enzyme inhibitors. Prior to joining Mission Therapeutics, Michael was Vice President of Clinical Sciences & Early Development at Glenmark Pharmaceuticals, where he led all clinical activities to progress Glenmark’s innovative drug portfolio. At Boehringer Ingelheim, he formed and managed a new group of Translational Medicine Experts to support and drive early drug development activities across all therapeutic areas at the company. Michael was also Group Leader of New Targets & Antibody Development at Ganymed Pharmaceuticals, and a Principal Scientist in Experimental & Translational Oncology at the University of Mainz, with focus on cancer drug target identification and the development of novel immunotherapeutics.

Michael has a degree in Medicine from the University of Cologne and a habilitation degree from the University of Mainz.